Nuformix Share Discussion Threads

[for fx sake] 21/3/2021 23:10

Oxilio is a tiny company with very little money. It is not Astrazeneca

[georgeo1] 21/3/2021 23:08

What's stopping from something like this happening.Redx shares soar after IPF drug licence deal with AstraZeneca.AstraZeneca has made a strong presence in China lately aswell looking to invest in early start ups.

[georgeo1] 21/3/2021 22:29

https://in-part.com/case-studies/newcastle-university-testing-proprietary-compounds/

[hollywood6] 21/3/2021 20:01

I hope the rise is due to the innovate grant.If its regarding Oxillo, what is a significant upfront payment? Will it be disclosed? Are you expecting huge share price rises from this? What will it add to the market cap? How will that reflect in the share price?

[georgeo1] 21/3/2021 19:48

Sounds good

[spurs90] 21/3/2021 19:24

Nfx
The rise on Friday imo could be attributed to one of 2 things

1– Innovate UK Grant for the further development of NXP002 which, if successful, would supplement investment and provide important non-dilutive funding for the lead asset

2 - Oxilio oncology option
The terms of its option agreement signed in September 2020 with Oxilio cover a licence for the development and exploitation of NXP001 in oncology. Deal terms include an undisclosed up-front payment to NFX offering an exclusive option period of 6 months, within which a global licensing agreement can be agreed, expiring 24 March 2021

VALUATION
We evaluate the lead programme and look at recent deals in the IPF space to illustrate the value of NFX and its lead asset as it advances its strategy and/or secures new deals over the next 12-18 months. We use a DCF approach to value the lead programme NXP002 assuming global development and as it approaches key inflection points. We accept that this is the key focus and with the most certainty at present, until there is greater clarity on the way forward for NXP001 and for NXP004. We take into account that the programme is still at an early stage, nevertheless that risk is reduced owing to the existing body of safety data on the underlying drug, and because of the abbreviated regulatory route applicable for repurposed co-crystal or new solid form therapies.
For simplicity, we look at the value of the asset as if NFX were to market the product, rather than via a licensing deal, to illustrate its worth to potential licensees. Our valuation of NXP002 as a preclinical asset using a 13% WACC gives a risk adjusted valuation of NFX of £52.8m which is equivalent to 9 pence per share (based on 591.6m shares in issue post funding). This assumes that a Phase I ready package for the asset is in place which is being developed over the next 12-18 months

NFX is looking to license the asset before Phase I, in which case we would anticipate a global deal value of between $360-450m, in upfront and milestone payments, plus single digit royalties on sales, increasing in value in proportion to the stage of development of the underlying asset: from feasibility up to the full Phase I ready GLP package, assuming successful outcomes and based on recent precedent. We illustrate a range of deal metrics in IPF to support our assumptions. Industry precedent shows that once a robust patent position is built, even early stage IPF assets are attracting significant deals in the indication. While pipelines are filling out, the novel approach, acute need and the inhaled route of administration are key factors that can differentiate NXP002.

NEWSFLOW
Over the next 12-18 months there are a number of possible events on the horizon:
– Initiation of the feasibility studies on NXP002 in Q2 2021
– OutcomedecisiononOxiliooptiononNXP001.
– News on patent filing outcomes, strategic path and partnering for NXP004 in oncology.
– Outcome of Innovate UK Grant Application for NXP002 in Q1 2021.
– Potential completion (subject to funding) of Phase I ready package for NXP002
by H1 2022.
– Partneringnewsacrossthepipeline.
– Corporate: FY results 12 months ended 31 March 2021 – date estimated
July/August

[georgeo1] 21/3/2021 18:51

What do you make of it.

[hollywood6] 21/3/2021 18:07

I've read the RNS

[georgeo1] 21/3/2021 14:26

General meeting on 29th if all goes ahead good to go. Oxilio licence if product. And more to go NXP002 NXP004.

[georgeo1] 20/3/2021 20:20

Looking back 3yr chart from March when NXP001 was released, it was a cracker same could happen on or after 23rd march.

[czar] 20/3/2021 16:44

This was over 12p last year, could we go beyond that?

[georgeo1] 20/3/2021 07:22

Clinical success with NXP001 demonstrates the potential for our wider pipeline. We now seek to replicate our approach of using known drugs to create value with reduced risk and costs of development to build a wider pipeline of innovative therapies. This will be achieved both with in-house programmes and in other collaborations, such as that announced previously with Ebers. We look forward to updating the market as we build on today's success to make progress both technically and commercially across the Nuformix portfolio."https://www.cambridgesciencepark.co.uk/news/nuformix-plc-positive-results-nxp001-clinical-tria-580/

[georgeo1] 20/3/2021 07:18

https://clinicaltrials.gov/ct2/show/NCT03889366

[georgeo1] 20/3/2021 07:11

Nufromix has three lead drugs under development: one for cancer (NPX001)and two for fibrosis including a potential treatment for IPF and latterly COVID-19.

[georgeo1] 20/3/2021 05:05

NXP004 is being investigated as a potential anti-fibrotic treatment for several fibrotic diseases, including IPF.

[georgeo1] 19/3/2021 23:16

https://youtu.be/e1MsFJczNLE

[leadersoffice] 19/3/2021 22:47

Don't be so negative

[georgeo1] 19/3/2021 19:13

Similar to HEMO.

[georgeo1] 19/3/2021 19:02

On 23 September last year, Nuformix granted Oxilio, a private pharmaceutical development company, an option to licence NXP001 globally for repurposing in oncology. Under the agreement, Oxilio has an exclusive option period that ends on March 23. Should Oxilio exercise the option and a global licence deal be negotiated, Nuformix will licence its patent estate and know-how on NXP001 in return for an upfront payment, development milestones and a royalty on net sales, capped at £2mln per annum. However, if the option is not exercised, Nuformix will pursue additional business development opportunities for NXP001 in oncology with the potential to generate value from this asset.https://www.google.com/amp/s/www.proactiveinvestors.co.uk/companies/amp/news/943458

[amaretto1] 19/3/2021 17:13

Never fails this company !!Never !!

[amaretto1] 19/3/2021 17:13

It's shocked me this share price actionMust be decent news coming.

[for fx sake] 19/3/2021 17:06

It's either leaked or rumoured news regarding Oxilio or the Innovate grant.The company have basically written off Ebers and Vistagen.

[soupdragon55] 19/3/2021 16:45

George, from March 2021 brokers note.

'Other alliances
Ebers and Vistagen: Previously the Group announced two agreements with third parties
centred on applying the Company’s IP and performing fee-for-service work on their
proprietary drugs. Whilst these agreements have provided Nuformix with undisclosed
revenue and certain milestone payments, these agreements are not material for the
Company’s ongoing strategy or future revenue.'